A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

Source: Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis


David Cottle

UBB Owner & Administrator